Butterfly Network heads into its third-quarter report having just posted the best quarter in its history, yet the setup calls for revenue to step down sequentially. That is not a contradiction so much as a reminder of how the business now works. The record $32.6 million second quarter was powered by embedded revenue of $10.8 million, much of it tied to milestone-based recognition from MidJourney, and management has framed the more durable embedded baseline at roughly $7 million to $8 million a quarter. This report will show how much of Butterfly's newfound momentum survives once that lumpy contribution normalizes, and whether the core handheld ultrasound franchise can pick up the slack.

The Street expects a loss of $0.05 per share on revenue of about $28.1 million. That would represent growth of roughly 31% from the $21.5 million reported a year ago and a sharp improvement from the year-ago loss of $0.13, though it would be a slightly wider loss than last quarter's $0.04. Consensus sits almost exactly at the midpoint of management's $26 million to $30 million guidance, and notably below the roughly $29.9 million analysts were carrying when that range was issued. In other words, estimates have already been pulled toward management's view, which lowers the bar for the top line. Management also flagged a wider adjusted EBITDA loss of $6 million to $9 million this quarter on stepped-up investment, so a modest per-share loss should not surprise anyone.

The more consequential questions sit beneath the headline. Core point-of-care ultrasound grew just 2% last quarter, down from 10% in the first quarter, while average selling prices fell 12% because of the subsidized IQ Plus devices in the medical school deal with VCOM. International revenue dropped 14%, with management attributing part of the decline to orders slipping into the third quarter. If those deferred orders show up and international returns to growth, the soft spot looks timing-related. If international stays weak and core growth remains in the low single digits, the argument that embedded wins are a supplement rather than a substitute for a healthy device business gets harder to make. Gross margin is another tell: the record 71% benefited from high-margin embedded revenue, so holding near 70% with a smaller embedded mix would be a meaningful sign of underlying improvement.

Management also stacked up near-term catalysts that this report can partly verify. Full FedRAMP certification for the Veterans Affairs channel was expected during the quarter, Home and Community Care went commercial on October 1 with revenue targeted for the fourth quarter, and three Garden partner AI tools are slated to launch by year end. The raised full-year outlook of $119 million to $123 million also implies a heavy fourth quarter, likely in the low-to-mid $30 million range if the third quarter lands near the midpoint. Any hint that those programs are slipping would put that back-half math at risk. Cash, which fell to $125 million after a $13.3 million burn, deserves attention given the higher investment pace.

Sentiment has warmed, with readings improving from decidedly bearish last quarter to only mildly bearish now, but the stock has not followed. Shares are up 2.7% since the last report, trailing the S&P 500, and at $7.31 they sit much closer to the post-earnings low of $6.74 than the $10.21 high, though still comfortably above the 200-day average near $5.92. The market appears to have taken the record quarter with some skepticism about its repeatability.

That skepticism frames the central issue. Butterfly does not need another blowout embedded quarter; it needs evidence that core demand, international orders and margins hold up when MidJourney contributes a normal amount, along with a reaffirmed full-year outlook. Deliver that, and the flywheel narrative gains credibility. Fall short on the core business, and last quarter's record may look more like a milestone than a trend.